缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明

doi:10.3969/j.issn.1673-5765.2024.08.012

中国卒中杂志 ›› 2024, Vol. 19 ›› Issue (8): 938-955.DOI: 10.3969/j.issn.1673-5765.2024.08.012

缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明

逯丹^1*，陈玮琪^2*，王雅平¹，段婉莹²，郭蕾²，王玲²，刘丽萍²，徐安定¹，王拥军^2，3，
中国卒中学会脑保护圆桌会学术委员会^{（*第一作者）}

1广州 510630暨南大学附属第一医院神经内科和卒中中心

2首都医科大学附属北京天坛医院神经病学中心
3国家神经系统疾病临床医学研究中心

收稿日期:2024-06-18 出版日期:2024-08-20 发布日期:2024-08-20
通讯作者: 王拥军yongjunwang1962@gmail.com 徐安定tlil@jnu.edu.cn 刘丽萍lipingsister@gmail.com

Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association

LU Dan^1*, CHEN Weiqi^2*, WANG Yaping¹, DUAN Wanying², GUO Lei², WANG Ling², LIU Liping², XU Anding¹, WANG Yongjun^2,3, Cerebroprotection Academic Roundtable Academic Committee of Chinese Stroke Association^{(*contributed equally)}

1Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China; 2Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 3China National Clinical Research Center for Neurological Diseases, Beijing 100070, China

Received:2024-06-18 Online:2024-08-20 Published:2024-08-20
Contact: WANG Yongjun, E-mail: yongjunwang1962@gmail.com XU Anding, E-mail: tlil@jnu.edu.cn LIU Liping, E-mail: lipingsister@gmail.com

摘要/Abstract

摘要： 缺血性卒中是致死致残的重症疾病之一。缺血性卒中患者预后不理想的重要原因之一是缺血级联反应造成的脑组织损伤。因此，积极的脑细胞保护治疗对改善缺血性卒中的预后至关重要。近年来，国内外大量临床前和临床研究证据层出不穷。基于更多新治疗靶点的涌现以及更多治疗方式的突破，结合最新卒中治疗学术产业圆桌会议的内容，本声明对缩小目前缺血性卒中研究临床转化鸿沟的探索、脑细胞保护的临床研究，以及如何有助于实现更多治疗方式的临床转化做一科学声明，旨在推进缺血性卒中脑细胞保护临床前及临床研究的开展，进一步改善缺血性卒中患者的临床预后。

关键词: 脑细胞保护; 缺血性卒中; 科学声明

Abstract: Ischemic stroke is one of the serious diseases that cause death and disability. One of the important reasons for the unsatisfactory prognosis of patients with ischemic stroke is the damage to brain tissue resulting from the ischemic cascade reaction. Therefore, active brain cytoprotection therapy is essential for ischemic stroke treatment. In recent years, evidence from many preclinical studies and clinical research has emerged at home and abroad. With the emergence of new therapeutic targets and breakthroughs in treatment approaches, combined with the content of the latest Stroke Treatment Academic Industry Roundtable, this paper makes a scientific statement on the exploration of strategies to bridge the gap of clinical transformation in ischemic stroke, clinical research on brain cytoprotection, and how can exploration contribute to the clinical transformation of more treatment approaches. The objective is to promote the development of preclinical studies and clinical research in brain cytoprotection for ischemic stroke, and further improve the clinical prognosis of patients with ischemic stroke.

Key words: Brain cytoprotection; Ischemic stroke; Scientific statement

中图分类号:

逯丹, 陈玮琪, 王雅平, 段婉莹, 郭蕾, 王玲, 刘丽萍, 徐安定, 王拥军, 中国卒中学会脑保护圆桌会学术委员会.

缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明 [J]. 中国卒中杂志, 2024, 19(8): 938-955.

LU Dan, CHEN Weiqi, WANG Yaping, DUAN Wanying, GUO Lei, WANG Ling, LIU Liping, XU Anding, WANG Yongjun, Cerebroprotection Academic Roundtable Academic Committee of Chinese Stroke Association .

Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association [J]. Chinese Journal of Stroke, 2024, 19(8): 938-955.

参考文献

[1] NIE X M，LENG X Y，MIAO Z R，et al. Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke[J]. Stroke，2023，54（3）：873-881.

[2] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2024-01-01]. https://doi.org/10.1161/STR.
0000000000000375.

[3] XIONG Y Y，WAKHLOO A K，FISHER M. Advances in acute ischemic stroke therapy[J]. Circ Res，2022，130（8）：1230-1251.

[4] Stroke Therapy Academic Industry Roundtable（STAIR）. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke，1999，30（12）：2752-2758.

[5] WECHSLER L R，ADEOYE O，ALEMSEGED F，et al. Most promising approaches to improve stroke outcomes：the Stroke Treatment Academic Industry Roundtable Ⅻ workshop[J]. Stroke，2023，54（12）：3202-3213.

[6] PARSONS A A，IRVING E A，LEGOS J J，et al. Acute stroke therapy：translating preclinical neuroprotection to therapeutic reality[J]. Curr Opin Investig Drugs，2000，1（4）：452-463.

[7] IADECOLA C. The neurovascular unit coming of age：a journey through neurovascular coupling in health and disease[J]. Neuron，2017，96（1）：17-42.

[8] SAVITZ S I，BARON J C，FISHER M，et al. Stroke Treatment Academic Industry Roundtable Ⅹ：brain cytoprotection therapies in the reperfusion era[J]. Stroke，2019，50（4）：1026-1031.

[9] IADECOLA C，SMITH E E，ANRATHER J，et al. The neurovasculome：key roles in brain health and cognitive impairment：a scientific statement from the American Heart Association/American Stroke Association[J/OL]. Stroke，2023，54（6）：e251-e271[2024-01-01]. https://doi.org/10.1161/STR.0000000000000431.

[10] 刘丽萍，周宏宇，段婉莹，等. 中国脑血管病临床管理指南（第2版）（节选）——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志，2023，18（8）：910-933.

LIU L P，ZHOU H Y，DUAN W Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）— chapter four clinical management of ischemic cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：910-933.

[11] XU X M，CHEN M Y，ZHU D Y. Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy：an overview of pathophysiology，pharmacological targets and candidate drugs focusing on excitotoxicity and free radical[J/OL]. Stroke Vasc Neurol，2023，svn-2023-002671[2024-01-01].
https://doi.org/10.1136/svn-2023-002671.

[12] HAN B，ZHANG Y，ZHANG Y H，et al. Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting miR142-TIPARP：implications for cerebral ischemic stroke[J]. Autophagy，2018，14（7）：1164-1184.

[13] BAI Y，ZHANG Y，HAN B，et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate endothelial-mesenchymal transition associated with blood-brain barrier integrity[J]. J Neurosci，2018，38（1）：32-50.

[14] YANG Z G，HUANG C，WEN X Y，et al. Circular RNA circ-FoxO3 attenuates blood-brain barrier damage by inducing autophagy during ischemia/reperfusion[J]. Mol Ther，2022，30（3）：1275-1287.

[15] LI B，XI W，BAI Y，et al. FTO-dependent m6A modification of Plpp3 in circSCMH1-regulated vascular repair and functional recovery following stroke
[J/OL]. Nat Commun，2023，14（1）：489[2024-01-01].
https://doi.org/10.1038/s41467-023-36008-y.

[16] LIU Y F，LI Y F，ZANG J K，et al. CircOGDH is a penumbra biomarker and therapeutic target in acute ischemic stroke[J]. Circ Res，2022，130（6）：907-924.

[17] LIU Y F，ZHANG T Y，ZOU X，et al. Penumbra-targeted circOGDH siRNA-loaded nanoparticles alleviate neuronal apoptosis in focal brain ischaemia[J]. Stroke Vasc Neurol，2024，9（2）：134-144.

[18] HU R Y，LIANG J，DING L，et al. Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke[J/OL]. Int Immunopharmacol，2022，113（Pt A）：109315
[2024-01-01]. https://doi.org/10.1016/j.intimp.2022.109315.

[19] HUANG Y X，ZHANG X J，ZHANG C，et al. Edaravone dexborneol downregulates neutrophil extracellular trap expression and ameliorates blood-brain barrier permeability in acute ischemic stroke[J/OL]. Mediators Inflamm，2022，2022（1）：3855698[2024-01-01].
https://doi.org/10.1155/2022/3855698.

[20] WANG D X，WANG Y T，SHI J F，et al. Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration[J/OL]. Int Immunopharmacol，2024，130：111700[2024-01-01]. https://doi.org/10.1016/j. intimp.2024.111700.

[21] ZHANG W，YANG H G，GAO M，et al. Edaravone dexborneol alleviates cerebral ischemic injury via MKP-1-mediated inhibition of MAPKs and activation of Nrf2[J/OL]. Biomed Res Int，2022，2022（1）：4013707
[2024-01-01]. https://doi.org/10.1155/2022/4013707.

[22] FU Y，WANG A X，TANG R H，et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke：the TASTE-SL randomized clinical trial[J]. JAMA Neurol，2024，81（4）：319-326.

[23] XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.

[24] HONG J M，CHOI M H，SOHN S I，et al. Safety and optimal neuroprotection of Neu2000 in acute ischemic stroke with recanalization：study protocol for a randomized，double-blinded，placebo-controlled，phase-Ⅱ trial[J/OL]. Trials，2018，19（1）：375
[2024-01-01]. https://doi.org/10.1186/s13063-018-2746-9.

[25] WU H Y，HUANG Z Q，WANG X，et al. Preclinical evaluation of ZL006-05，a new antistroke drug with fast-onset antidepressant and anxiolytic effects[J]. Stroke Vasc Neurol，2023，8（6）：463-474.

[26] ZHU T，WANG L，WANG L P，et al. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke：applications for natural compounds from medicinal herbs[J/OL]. Biomed Pharmacother，2022，148：112719[2024-01-01]. https://doi.org/10.1016/j.
biopha.2022.112719.

[27] FANG W R，SHA L，KODITHUWAKKU N D，et al. Attenuated blood-brain barrier dysfunction by XQ-1H following ischemic stroke in hyperlipidemic rats[J]. Mol Neurobiol，2015，52（1）：162-175.

[28] ZHOU X，WANG H Y，WU B，et al. Ginkgolide K attenuates neuronal injury after ischemic stroke by inhibiting mitochondrial fission and GSK-3β-dependent increases in mitochondrial membrane permeability[J]. Oncotarget，2017，8（27）：44682-44693.

[29] YE H B，MA Z F，LIU L，et al. Thrombus inhibition and neuroprotection for ischemic stroke treatment through platelet regulation and ROS scavenging[J/OL]. ChemMedChem，2022，17（24）：e202200317[2024-01-01]. https://doi.org/10.1002/cmdc.202200317.

[30] LI B，ZHANG B K，LI Z Y，et al. Ginkgolide C attenuates cerebral ischemia/reperfusion-induced inflammatory impairments by suppressing CD40/NF-κB pathway
[J/OL]. J Ethnopharmacol，2023，312：116537[2024-01-01].
https://doi.org/10.1016/j.jep.2023.116537.

[31] DONG Y，ZHANG J Y，WANG Y X，et al. Effect of ginkgolide in ischemic stroke patients with large artery atherosclerosis：results from a randomized trial[J]. CNS Neurosci Ther，2021，27（12）：1561-1569.

[32] ZHANG X T，ZHONG W S，MA X D，et al. Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke improving neurological function：a multicenter，cluster-randomized trial（GIANT）
[J/OL]. Front Pharmacol，2021，12：792136[2024-01-01].
https://doi.org/10.3389/fphar.2021.792136.

[33] SAVER J L，ALBERS G W，DUNN B，et al. Stroke Therapy Academic Industry Roundtable（STAIR）recommendations for extended window acute stroke therapy trials[J]. Stroke，2009，40（7）：2594-2600.

[34] LYDEN P，BUCHAN A，BOLTZE J，et al. Top priorities for cerebroprotective studies—a paradigm shift：report from STAIR Ⅺ[J]. Stroke，2021，52（9）：3063-3071.

[35] SAVER J L，STARKMAN S，ECKSTEIN M，et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke[J]. N Engl J Med，2015，372（6）：528-536.

[36] PERCIE DU SERT N，HURST V，AHLUWALIA A，et al. The ARRIVE guidelines 2.0：updated guidelines for reporting animal research[J/OL]. BMC Vet Res，2020，16（1）：242[2024-01-01]. https://doi.org/10.1186/s12917-020-02451-y.

[37] PAUL S，CANDELARIO-JALIL E. Emerging neuroprotective strategies for the treatment of ischemic stroke：an overview of clinical and preclinical studies
[J/OL]. Exp Neurol，2021，335：113518[2024-01-01]. https://doi.org/10.1016/j.expneurol.2020.113518.

[38] BOSETTI F，KOENIG J I，JANIS L S，et al. Organizational update：the NINDS-sponsored stroke preclinical assessment network is moving to its next stage
[J/OL]. Stroke，2021，52（12）：e842-e843[2024-01-01]. https://doi.org/10.1161/STROKEAHA.121.035885.

[39] LYDEN P D，BOSETTI F，DINIZ M A，et al. The stroke preclinical assessment network：rationale，design，feasibility，and stage 1 results[J]. Stroke，2022，53（5）：1802-1812.

[40] HARRIS P A，TAYLOR R，MINOR B L，et al. The REDCap consortium：building an international community of software platform partners[J/OL]. J Biomed Inform，2019，95：103208[2024-01-01].
https://doi.org/10.1016/j.jbi.2019.103208.

[41] LEES K R，KHATRI P，STAIR IX COLLABORATORS. Stroke Treatment Academic Industry Roundtable recommendations for individual data pooling analyses in stroke[J]. Stroke，2016，47（8）：2154-2159.

[42] BOSETTI F，KOENIG J I，AYATA C，et al. Translational stroke research：vision and opportunities[J]. Stroke，2017，48（9）：2632-2637.

[43] VOELKL B，VOGT L，SENA E S，et al. Reproducibility of preclinical animal research improves with heterogeneity of study samples[J/OL]. PLoS Biol，2018，16（2）：e2003693[2024-01-01]. https://doi.org/10.1371/journal.pbio.2003693.

[44] RIJO-FERREIRA F，TAKAHASHI J S. Genomics of circadian rhythms in health and disease[J/OL]. Genome Med，2019，11（1）：82[2024-01-01]. https://doi.org/10.1186/s13073-019-0704-0.

[45] KRINGE L，SENA E S，MOTSCHALL E，et al. Quality and validity of large animal experiments in stroke：a systematic review[J]. J Cereb Blood Flow Metab，2020，40（11）：2152-2164.

[46] ESPOSITO E，LI W L，MANDEVILLE E T，et al. Potential circadian effects on translational failure for neuroprotection[J]. Nature，2020，582（7812）：395-398.

[47] SAVER J L，CHAISINANUNKUL N，CAMPBELL B C V，et al. Standardized nomenclature for modified Rankin scale global disability outcomes：consensus recommendations from Stroke Therapy Academic Industry Roundtable Ⅺ[J]. Stroke，2021，52（9）：3054-3062.

[48] CAMPBELL B C V，LANSBERG M G，BRODERICK J P，et al. Acute Stroke Imaging Research Roadmap Ⅳ：imaging selection and outcomes in acute stroke clinical trials and practice[J]. Stroke，2021，52（8）：2723-2733.

[49] OLIVé-GADEA M，REQUENA M，CAMPOS D，et al. Defining a target population to effectively test a neuroprotective drug[J]. Stroke，2021，52（2）：505-510.

[50] SAMANIEGO E A，BOLTZE J，LYDEN P D，et al. Priorities for advancements in neuroimaging in the diagnostic workup of acute stroke[J]. Stroke，2023，54（12）：3190-3201.

[51] TETTAMANTI M，BERETTA S，PIGNATARO G，et al. Multicentre translational trial of remote ischaemic conditioning in acute ischaemic stroke（TRICS）：protocol of multicentre，parallel group，randomised，preclinical trial in female and male rat and mouse from the Italian Stroke Organization（ISO）basic science network[J/OL]. BMJ Open Sci，2020，4（1）：e100063[2024-01-01]. https://doi.org/10.1136/bmjos-2020-100063.

[52] RIPLEY A J，JEFFERS M S，MCDONALD M W，et al. Neuroprotection by remote ischemic conditioning in rodent models of focal ischemia：a systematic review and meta-analysis[J]. Transl Stroke Res，2021，12（3）：461-473.

[53] DIAZ DIAZ A C，MALONE K，SHEARER J A，et al. Histological，behavioural and flow cytometric datasets relating to acute ischaemic stroke in young，aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod[J/OL]. Data Brief，2021，36：107146[2024-01-01]. https://doi.org/10.1016/j.dib.2021.107146.

[54] USUI T，MACLEOD M R，MCCANN S K，et al. Meta-analysis of variation suggests that embracing variability improves both replicability and generalizability in preclinical research[J/OL]. PLoS Biol，2021，19（5）：e3001009[2024-01-01]. https://doi.org/10.1371/journal.pbio.3001009.

[55] MORAIS A，LOCASCIO J J，SANSING L H，et al. Embracing heterogeneity in the multicenter stroke preclinical assessment network（SPAN）trial[J]. Stroke，2023，54（2）：620-631.

[56] MUIR K W，LEES K R，FORD I，et al. Magnesium for acute stroke（intravenous magnesium efficacy in stroke trial）：randomised controlled trial[J]. Lancet，2004，363（9407）：439-445.

[57] DIXON M，APPLETON J P，SCUTT P，et al. Time intervals and distances travelled for prehospital ambulance stroke care：data from the randomised-controlled ambulance-based rapid intervention with glyceryl trinitrate in hypertensive stroke trial-2（RIGHT-2）[J/OL]. BMJ Open，2022，12（11）：e060211[2024-01-01]. https://doi.org/10.1136/bmjopen-2021-060211.

[58] LEES K R，ZIVIN J A，ASHWOOD T，et al. NXY-059 for acute ischemic stroke[J]. N Engl J Med，2006，354（6）：588-600.

[59] SHUAIB A，LEES K R，LYDEN P，et al. NXY-059 for the treatment of acute ischemic stroke[J]. N Engl J Med，2007，357（6）：562-571.

[60] FIDALGO M，RICARDO PIRES J，VISEU I，et al. Edaravone for acute ischemic stroke—systematic review with meta-analysis[J/OL]. Clin Neurol Neurosurg，2022，219：107299[2024-01-01]. https://doi.org/10.1016/j.clineuro.2022.107299.

[61] NI J，YAO M，WANG L H，et al. Human urinary kallidinogenase in acute ischemic stroke：a single-arm，multicenter，phase Ⅳ study（RESK study）[J]. CNS Neurosci Ther，2021，27（12）：1493-1503.

[62] HAUPT M，GERNER S T，BÄHR M，et al. Quest for quality in translational stroke research—a new dawn for neuroprotection？[J/OL]. Int J Mol Sci，2022，23（10）：5381[2024-01-01]. https://doi.org/10.3390/ijms23105381.

[63] WANG C J，GU H Q，DONG Q，et al. Rationale and design of treatment of acute ischaemic stroke with edaravone dexborneol Ⅱ（TASTE-2）：a multicentre randomised controlled trial[J/OL]. Stroke Vasc Neurol，2024：svn-2023-002938[2024-01-01]. https://doi.org/10.1136/svn-2023-002938.

[64] TIAN D C，SHI K B，ZHU Z L，et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow[J]. Ann Neurol，2018，84（5）：717-728.

[65] CHENG Z，GAO J，DING Y，et al. Arterial glyceryl trinitrate in acute ischemic stroke after thrombectomy for neuroprotection（AGAIN）：a pilot randomized controlled trial[J]. Neurotherapeutics，2023，20（6）：1746-1754.

[66] CHAMORRO A，AMARO S，CASTELLANOS M，et al. Safety and efficacy of uric acid in patients with acute stroke（URICO-ICTUS）：a randomised，double-blind phase 2b/3 trial[J]. Lancet Neurol，2014，13（5）：453-460.

[67] PRASAD K，SHARMA A，GARG A，et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke：a multicentric，randomized trial[J]. Stroke，2014，45（12）：3618-3624.

[68] JAILLARD A，HOMMEL M，MOISAN A，et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke：a randomized clinical trial[J]. Transl Stroke Res，2020，11（5）：910-923.

[69] CHABRIAT H，BASSETTI C L，MARX U，et al. Safety and efficacy of GABAAα5 antagonist S44819 in patients with ischaemic stroke：a multicentre，double-blind，randomised，placebo-controlled trial[J]. Lancet Neurol，2020，19（3）：226-233.

[70] GONZáLEZ-NIETO D，FERNáNDEZ-SERRA R，PéREZ-RIGUEIRO J，et al. Biomaterials to neuroprotect the stroke brain：a large opportunity for narrow time windows[J/OL]. Cells，2020，9（5）：1074[2024-01-01]. https://doi.org/10.3390/cells9051074.

[71] DáVALOS A，ALVAREZ-SABíN J，CASTILLO J，et al. Citicoline in the treatment of acute ischaemic stroke：an international，randomised，multicentre，placebo-controlled study（ICTUS trial）[J]. Lancet，2012，380（9839）：349-357.

[72] ZHU X Y，MA T T，LI Y，et al. Fingolimod protects against neurovascular unit injury in a rat model of focal cerebral ischemia/reperfusion injury[J]. Neural Regen Res，2023，18（4）：869-874.

[73] LóPEZ-VALDéS H E，CLARKSON A N，AO Y，et al. Memantine enhances recovery from stroke[J]. Stroke，2014，45（7）：2093-2100.

[74] ZHENG H G，WANG Y L，WANG A X，et al. The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment：a double-blind，randomized，placebo-controlled trial[J]. Sci Bull（Beijing），2019，64（2）：101-107.

[75] CHUNG J W，CHANG W H，BANG O Y，et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke[J/OL]. Neurology，2021，96（7）：e1012-e1023[2024-01-01]. https://doi.org/10.1212/WNL.0000000000011440.

[76] ZHONG J，LI R W，WANG J，et al. Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke[J]. Neural Regen Res，2021，16（2）：312-318.

[77] LI S Y，JIANG D W，EHLERDING E B，et al. Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury[J]. ACS Nano，2019，13（11）：13382-13389.

[78] KALLADKA D，SINDEN J，POLLOCK K，et al. Human neural stem cells in patients with chronic ischaemic stroke（PISCES）：a phase 1，first-in-man study[J]. Lancet，2016，388（10046）：787-796.

[79] MENG R，DING Y C，ASMARO K，et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment[J]. Neurotherapeutics，2015，12（3）：667-677.

[80] ZHOU D，DING J Y，YA J Y，et al. Efficacy of remote ischemic conditioning on improving WMHs and cognition in very elderly patients with intracranial atherosclerotic stenosis[J]. Aging（Albany NY），2019，11（2）：634-648.

[81] HOU C B，LAN J，LIN Y N，et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis（the RICA trial）：a multicentre，randomised，double-blind sham-controlled trial in China[J]. Lancet Neurol，2022，21（12）：1089-1098.

[82] ENGLAND T J，HEDSTROM A，O’SULLIVAN S，et al. RECAST（remote ischemic conditioning after stroke trial）：a pilot randomized placebo controlled phase Ⅱ trial in acute ischemic stroke[J]. Stroke，2017，48（5）：1412-1415.

[83] ENGLAND T J，HEDSTROM A，O’SULLIVAN S E，et al. Remote ischemic conditioning after stroke trial 2：a phase Ⅱb randomized controlled trial in hyperacute stroke[J/OL]. J Am Heart Assoc，2019，8（23）：e013572[2024-01-01]. https://doi.org/10.1161/JAHA.119.013572.

[84] CHEN H S，CUI Y，LI X Q，et al. Effect of remote ischemic conditioning vs. usual care on neurologic function in patients with acute moderate ischemic stroke：the RICAMIS randomized clinical trial[J]. JAMA，2022，328（7）：627-636.

[85] ZHAO W B，CHE R W，LI S J，et al. Remote ischemic conditioning for acute stroke patients treated with thrombectomy[J]. Ann Clin Transl Neurol，2018，5（7）：850-856.

[86] HOUGAARD K D，HJORT N，ZEIDLER D，et al. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke：a randomized trial[J]. Stroke，2014，45（1）：159-167.

[87] CHE R W，ZHAO W B，MA Q F，et al. rt-PA with remote ischemic postconditioning for acute ischemic stroke[J]. Ann Clin Transl Neurol，2019，6（2）：364-372.

[88] AN J Q，CHENG Y W，GUO Y C，et al. Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke[J/OL]. Neurology，2020，95（24）：e3355-e3363[2024-01-01]. https://doi.org/10.1212/WNL.0000000000010884.

[89] WANG Y，MENG R，SONG H Q，et al. Remote ischemic conditioning may improve outcomes of patients with cerebral small-vessel disease[J]. Stroke，2017，48（11）：3064-3072.

[90] MI T M，YU F，JI X M，et al. The interventional effect of remote ischemic preconditioning on cerebral small vessel disease：a pilot randomized clinical trial[J]. Eur Neurol，2016，76（1/2）：28-34.

[91] SU Y Y，FAN L L，ZHANG Y Z，et al. Improved neurological outcome with mild hypothermia in surviving patients with massive cerebral hemispheric infarction[J]. Stroke，2016，47（2）：457-463.

[92] PIIRONEN K，TIAINEN M，MUSTANOJA S，et al. Mild hypothermia after intravenous thrombolysis in patients with acute stroke：a randomized controlled trial[J]. Stroke，2014，45（2）：486-491.

[93] HEMMEN T M，RAMAN R，GULUMA K Z，et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke（ICTuS-L）：final results[J]. Stroke，2010，41（10）：2265-2270.

[94] LYDEN P，HEMMEN T，GROTTA J，et al. Results of the ICTuS 2 trial（intravascular cooling in the treatment of stroke 2）[J]. Stroke，2016，47（12）：2888-2895.

[95] HORN C M，SUN C H J，NOGUEIRA R G，et al. Endovascular reperfusion and cooling in cerebral acute ischemia（ReCCLAIMI）[J]. J Neurointerv Surg，2014，6（2）：91-95.

[96] HONG J M，LEE J S，SONG H J，et al. Therapeutic hypothermia after recanalization in patients with acute ischemic stroke[J]. Stroke，2014，45（1）：134-140.

[97] CHENG Z，DING Y C，RAJAH G B，et al. Vertebrobasilar artery cooling infusion in acute ischemic stroke for posterior circulation following thrombectomy：rationale，design and protocol for a prospective randomized controlled trial[J/OL]. Front Neurosci，2023，17：1149767[2024-01-01]. https://doi.org/10.3389/fnins.2023.1149767.

[98] APPLEBAUM R M，KASLIWAL R，TUNICK P A，et al. Sequential external counterpulsation increases cerebral and renal blood flow[J]. Am Heart J，1997，133（6）：611-615.

[99] HAN J H，LEUNG T W，LAM W W，et al. Preliminary findings of external counterpulsation for ischemic stroke patient with large artery occlusive disease[J]. Stroke，2008，39（4）：1340-1343.

[100] XIONG L，LIN W H，HAN J H，et al. Enhancing cerebral perfusion with external counterpulsation after ischaemic stroke：how long does it last？[J]. J Neurol Neurosurg Psychiatry，2016，87（5）：531-536.

[101] LIN W H，HAN J H，CHEN X Y，et al. Predictors of good functional outcome in counterpulsation-treated recent ischaemic stroke patients[J/OL]. BMJ Open，2013，3（6）：e002932[2024-01-01]. https://doi.org/10.1136/bmjopen-2013-002932.

[102] LIN W H，XIONG L，HAN J H，et al. Increasing pressure of external counterpulsation augments blood pressure but not cerebral blood flow velocity in ischemic stroke[J]. J Clin Neurosci，2014，21（7）：1148-1152.

[103] TIAN G，XIONG L，LIN W H，et al. External counterpulsation reduces beat-to-beat blood pressure variability when augmenting blood pressure and cerebral blood flow in ischemic stroke[J]. J Clin Neurol，2016，12（3）：308-315.

[104] XIONG L，TIAN G，WANG L，et al. External counterpulsation increases beat-to-beat heart rate variability in patients with ischemic stroke[J]. J Stroke Cerebrovasc Dis，2017，26（7）：1487-1492.

[105] HAMMER M D，SCHWAMM L，STARKMAN S，et al. Safety and feasibility of NeuroFlo use in eight-to
24-hour ischemic stroke patients[J]. Int J Stroke，2012，7（8）：655-661.

[106] SHUAIB A，BORNSTEIN N M，DIENER H C，et al. Partial aortic occlusion for cerebral perfusion augmentation：safety and efficacy of NeuroFlo in acute ischemic stroke trial[J]. Stroke，2011，42（6）：1680-1690.

[107] LEVI H，SCHOKNECHT K，PRAGER O，et al. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model[J/OL]. PloS One，2012，7（6）：e39636[2024-01-01]. https://doi.org/10.1371/journal.pone.0039636.

[108] BORNSTEIN N M，SAVER J L，DIENER H C，et al. Sphenopalatine ganglion stimulation to augment cerebral blood flow：a randomized，sham-controlled trial[J]. Stroke，2019，50（8）：2108-2117.

[109] BORNSTEIN N M，SAVER J L，DIENER H C，et al. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset（ImpACT-24B）：an international，randomised，double-blind，sham-controlled，pivotal trial[J]. Lancet，2019，394（10194）：219-229.

缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明

Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张梦若, 徐守臣, 隋翠翠, 李玉奎, 王雪莉. 下肢康复机器人联合头针治疗对老年缺血性卒中患者步行效率和协调功能影响调查 [J]. 中国卒中杂志, 2024, 19(8): 902-908.
[2]	吴娱倩, 张玉梅, 臧大维, 范小伟, 王安心, 张晓丽, 孟霞. 上肢动作研究测试量表评定亚急性期缺血性卒中患者偏瘫侧上肢及手功能的信效度和敏感性研究 [J]. 中国卒中杂志, 2024, 19(8): 915-923.
[3]	莫秋红, 丁晓波, 李靓, 张岩波, 李伟荣. 基于可解释性机器学习模型的轻型缺血性卒中复发预测研[J]. 中国卒中杂志, 2024, 19(8): 924-930.
[4]	李光硕, 赵性泉. 《中国急性缺血性卒中诊治指南2023》解读[J]. 中国卒中杂志, 2024, 19(8): 956-961.
[5]	白磊鹏, 罗杰, 周思捷, 黄健辉, 梁铭钦, 赵庆顺. 肺叶楔形切除术后并发急性缺血性卒中行介入取栓治疗2例并文献回顾 [J]. 中国卒中杂志, 2024, 19(8): 962-966.
[6]	赵岩, 姚婧鑫, 彭宇明. 老年开颅肿瘤切除患者围手术期同时并发缺血性卒中及脑出血报道 [J]. 中国卒中杂志, 2024, 19(7): 797-802.
[7]	李彦江, 刘彤晖, 田惠, 孙岩, 张勇. 药物涂层球囊与普通球囊血管成形术治疗症状性颅内动脉粥样硬化性狭窄的安全性和预后对比研究 [J]. 中国卒中杂志, 2024, 19(7): 803-808.
[8]	伊珞, 姜英玉, 孟霞, 姜勇, 王拥军, 谷鸿秋. 轻型急性缺血性卒中患者院内神经功能恶化预测模型的开发与验证研究[J]. 中国卒中杂志, 2024, 19(5): 524-531.
[9]	郑国民, 梁志刚, 张振. 替罗非班联合机械取栓治疗急性缺血性卒中的研究进展[J]. 中国卒中杂志, 2024, 19(5): 573-578.
[10]	中国卒中学会医疗质量管理与促进分会, 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组. 中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明[J]. 中国卒中杂志, 2024, 19(4): 440-451.
[11]	郝曼均, 王利圆, 熊云云. 再灌注治疗的神经影像学评估[J]. 中国卒中杂志, 2024, 19(4): 459-467.
[12]	丁则昱, 李光硕, 赵性泉. 高水平空腹血糖与缺血性卒中患者静脉溶栓后功能结局的关系分析[J]. 中国卒中杂志, 2024, 19(3): 293-298.
[13]	陈思嘉, 潘培炎, 陈思琪, 彭菲, 米东华. 普罗布考联合他汀类药物治疗颈动脉斑块的meta分析[J]. 中国卒中杂志, 2024, 19(3): 299-309.
[14]	闫喜格, 王国玲, 张博刚, 彭敏, 董中君, 申晓平, 陈秀晓, 贾倩, 董会格, 程莉. 急性颈动脉闭塞支架置入术后血管再闭塞补救性治疗方法——股-颈动脉转流术报道[J]. 中国卒中杂志, 2024, 19(3): 331-336.
[15]	刘亚飞, 吴亭亭, 闫世曦, 贾崇, 张邯菲, 张忠波, 武一平. 急性缺血性卒中梗死核心体积的影像学评估应用进展[J]. 中国卒中杂志, 2024, 19(3): 349-355.